Date: 2017-01-09
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 9, 2017, Adaptimmune Therapeutics announced that Mark E. Dudley, Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development. Dr. Dudley has been a pioneer in the field of immunotherapy manufacturing, and has developed and implemented innovative early process design with accompanying analytics for multiple therapies. Prior to joining Adaptimmune, Dr. Dudley was the Director of New Cell Products for Cell and Gene Therapy at Novartis in Cambridge, MA where he served on the technical R&D leadership team, and was responsible for establishing scalable, GMP?compliant production strategies, and facilitating globalization of CAR-T products and platforms. Prior to joining Novartis, Dr. Dudley served as Director of the Cell Production Facility at the National Cancer Institute (NCI) in Bethesda, MD where he also led scientific and technical innovation enabling key milestones in immuno-oncology success. Dr. Dudley’s work has resulted in more than 100 peer-reviewed publications, and he is co-author on numerous seminal papers including early tumor-infiltrating lymphocytes studies demonstrating that adoptive T-cell transfer has tumor eradicating potential. Before joining the NIH and subsequently Novartis, Dr. Dudley earned his Ph.D. in Biological Sciences at Stanford University, and had post-doctoral fellowships at The University of Pennsylvania in Philadelphia, PA, and at the Jackson Laboratory in Bar Harbor, ME.
Financial terms:
Latest news:
